ARTV4:05 PMArtiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conferenceartivabio.com
ARTV6:30 AMArtiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast TodayPresentation / Abstractartivabio.com
ARTV8:00 AMArtiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conferenceartivabio.com
ARTV4:05 PMArtiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseasesartivabio.com
ARTV8:00 AMArtiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Developmentartivabio.com
ARTV6:52 AMArtiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrantsartivabio.com
ARTV6:31 AMArtiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlightsartivabio.com
ARTV6:30 AMArtiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026artivabio.com